Associations between MSI as determined by the panel of 12 markers and exogenous hormone
| OR (referent)a | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
|---|---|---|---|---|
| Oral contraceptive use | Never | Ever | ||
| MSI+/MSI−/control | 121/392/817 | 24/133/280 | ||
| MSI+ vs. control | 1.0 | 0.6 (0.4–1.1) | ||
| MSI− vs. control | 1.0 | 0.9 (0.7–1.2) | ||
| MSI+ vs. MSI− | 1.0 | 0.7 (0.4–1.2) | ||
| HRTb | Never | Everc | Recentd | Formere |
| MSI+/MSI−/control | 83/326/628 | 46/161/354 | 23/115/260 | 23/46/94 |
| MSI+ vs. control | 1.0 | 1.0 (0.7–1.5) | 0.7 (0.4–1.1) | 1.8 (1.1–3.1) |
| MSI− vs. control | 1.0 | 0.9 (0.7–1.1) | 0.9 (0.7–1.1) | 1.0 (0.7–1.4) |
| MSI+ vs. MSI− | 1.0 | 1.2 (0.8–1.8) | 0.8 (0.5–1.4) | 2.0 (1.1–3.5) |
a Adjusted for age, energy intake.
b Analyses restricted to postmenopausal women.
c Ever used for 3 months or longer.
d In the year prior to referent date.
e Having stopped 2 years prior to the referent date.